Genetic testing for specific mutations, such as the BRAF V600E mutation in melanoma or EGFR mutations in lung cancer, helps identify targeted therapies that selectively inhibit cancer cell growth and improve patient outcomes. This evidence concerns the gene BRAF and melanoma.